Valuation: BioNTech SE

Market Cap 20.27B 23.35B 18.9B 17.37B 32.84B 2,221B 33.2B 223B 87.12B 1,110B 87.69B 85.76B 3,679B P/E 2026 *
-18.2x
P/E 2027 * -17.6x
Enterprise Value 9.42B 10.85B 8.79B 8.07B 15.27B 1,032B 15.43B 104B 40.5B 516B 40.76B 39.87B 1,710B EV / Sales 2026 *
4.35x
EV / Sales 2027 * 4.93x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day+0.88%
1 week+0.97%
Current month+3.06%
1 month-0.62%
3 months-6.04%
6 months-14.18%
Current year-1.94%
1 week 88.2
Extreme 88.2
94.41
1 month 88.2
Extreme 88.2
95.89
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
18/3/26 Other

Director

1,927 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%+0.97%-15.16%-12.33% 23.33B
+10.00%+13.39%+51.99%+83.45% 56.7B
+0.80%-5.70%+23.89%+62.65% 51.97B
+0.66%-4.82%-10.90%+350.70% 21.34B
+1.73%-1.57%+32.81%-25.80% 17.44B
+4.29%+1.67%+201.24%+344.48% 14.77B
+2.03%-0.80%+52.30%+176.57% 13.84B
+2.83%+2.52%+434.10%+177.85% 12.12B
+5.24%-6.41%+61.57%+159.30% 11.14B
+2.30%-2.23%+112.36%+134.05% 10.38B
Average +3.06%-1.08%+94.42%+145.09% 23.3B
Weighted average by Cap. +3.77%+0.19%+64.30%+118.38%

Financials

2026 *2027 *
Net sales 2.17B 2.5B 2.02B 1.86B 3.51B 238B 3.55B 23.83B 9.32B 119B 9.38B 9.17B 393B 2.23B 2.57B 2.08B 1.91B 3.61B 244B 3.65B 24.52B 9.59B 122B 9.65B 9.44B 405B
Net income -1.04B -1.2B -974M -894M -1.69B -114B -1.71B -11.48B -4.49B -57.19B -4.52B -4.42B -189B -1.16B -1.34B -1.09B -998M -1.89B -128B -1.91B -12.8B -5B -63.78B -5.04B -4.93B -211B
Net Debt -10.85B -12.5B -10.12B -9.29B -17.58B -1,189B -17.77B -119B -46.62B -594B -46.93B -45.9B -1,969B -9.28B -10.69B -8.65B -7.95B -15.03B -1,017B -15.2B -102B -39.88B -508B -40.14B -39.26B -1,684B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
05/08/26 US$93.32 +1.16% 900,644
03/08/26 US$92.25 +1.84% 1,119,580
31/07/26 US$90.58 -2.44% 710,906
30/07/26 US$92.85 -0.11% 1,381,280
29/07/26 US$92.95 +0.54% 740,136
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
80.17EUR
Average target price
107.04EUR
Spread / Average Target
+33.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock